Overview

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

Status:
Terminated
Trial end date:
2016-08-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.
Phase:
Phase 2
Details
Lead Sponsor:
Karyopharm Therapeutics Inc
Karyopharm Therapeutics, Inc